CoChat

Therapeutic Modulation of RNA Splicing in Malignant and Non-Malignant Disease

El Marabti, Ettaib, Abdel-Wahab, Omar · 2021 · Trends in Molecular Medicine
Cited by 71

The DOI matches its Crossref record; 13 of the 13 references it cites were found in a registry or an index.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.molmed.2021.04.005

Cites

13 of 13 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Research works printed but not linked: 156

  1. Doolittle, 1978, Genes in pieces: were they ever together?, Nature, 272, 581, 10.1038/272581a0 · DOI · Paper page
  2. Matlin, 2005, Understanding alternative splicing: towards a cellular code, Nat. Rev. Mol. Cell Biol., 6, 386, 10.1038/nrm1645 · DOI · Paper page
  3. Blencowe, 2006, Alternative splicing: new insights from global analyses, Cell, 126, 37, 10.1016/j.cell.2006.06.023 · DOI · Paper page
  4. Wang, 2008, Splicing regulation: from a parts list of regulatory elements to an integrated splicing code, RNA, 14, 802, 10.1261/rna.876308 · DOI · Paper page
  5. Schaal, 1999, Multiple distinct splicing enhancers in the protein-coding sequences of a constitutively spliced pre-mRNA, Mol. Cell. Biol., 19, 261, 10.1128/MCB.19.1.261 · DOI · Paper page
  6. Fairbrother, 2002, Predictive identification of exonic splicing enhancers in human genes, Science, 297, 1007, 10.1126/science.1073774 · DOI · Paper page
  7. Jobbins, 2018, The mechanisms of a mammalian splicing enhancer, Nucleic Acids Res., 46, 2145, 10.1093/nar/gky056 · DOI
  8. Pozzoli, 2005, Silencers regulate both constitutive and alternative splicing events in mammals, Cell. Mol. Life Sci., 62, 1579, 10.1007/s00018-005-5030-6 · DOI
  9. Wang, 2006, General and specific functions of exonic splicing silencers in splicing control, Mol. Cell, 23, 61, 10.1016/j.molcel.2006.05.018 · DOI · Paper page
  10. Ladd, 2002, Finding signals that regulate alternative splicing in the post-genomic era, Genome Biol., 3, 10.1186/gb-2002-3-11-reviews0008 · DOI
  11. Scamborova, 2004, An intronic enhancer regulates splicing of the twintron of Drosophila melanogaster prospero pre-mRNA by two different spliceosomes, Mol. Cell. Biol., 24, 1855, 10.1128/MCB.24.5.1855-1869.2004 · DOI
  12. Wang, 2012, Intronic splicing enhancers, cognate splicing factors and context-dependent regulation rules, Nat. Struct. Mol. Biol., 19, 1044, 10.1038/nsmb.2377 · DOI · Paper page
  13. Zheng, 2004, Regulation of alternative RNA splicing by exon definition and exon sequences in viral and mammalian gene expression, J. Biomed. Sci., 11, 278, 10.1007/BF02254432 · DOI · Paper page
  14. Busch, 2012, Evolution of SR protein and hnRNP splicing regulatory factors, Wiley Interdiscip. Rev. RNA, 3, 1, 10.1002/wrna.100 · DOI · Paper page
  15. Graveley, 2000, Sorting out the complexity of SR protein functions, RNA, 6, 1197, 10.1017/S1355838200000960 · DOI · Paper page
  16. Shepard, 2009, The SR protein family, Genome Biol., 10, 242, 10.1186/gb-2009-10-10-242 · DOI · Paper page
  17. Scotti, 2016, RNA mis-splicing in disease, Nat. Rev. Genet., 17, 19, 10.1038/nrg.2015.3 · DOI · Paper page
  18. Verma, 2018, Minor spliceosome and disease, Semin. Cell Dev. Biol., 79, 103, 10.1016/j.semcdb.2017.09.036 · DOI
  19. Krawczak, 2007, Single base-pair substitutions in exon–intron junctions of human genes: nature, distribution, and consequences for mRNA splicing, Hum. Mutat., 28, 150, 10.1002/humu.20400 · DOI · Paper page
  20. Lim, 2011, Using positional distribution to identify splicing elements and predict pre-mRNA processing defects in human genes, Proc. Natl. Acad. Sci. U. S. A., 108, 11093, 10.1073/pnas.1101135108 · DOI · Paper page
  21. Mueller, 2015, The silent sway of splicing by synonymous substitutions, J. Biol. Chem., 290, 27700, 10.1074/jbc.M115.684035 · DOI
  22. Lee, 2016, Therapeutic targeting of splicing in cancer, Nat. Med., 22, 976, 10.1038/nm.4165 · DOI · Paper page
  23. Baumgartner, 2018, Minor spliceosome inactivation causes microcephaly, owing to cell cycle defects and death of self-amplifying radial glial cells, Development, 145, 10.1242/dev.166322 · DOI · Paper page
  24. Sune-Pou, 2020, Innovative therapeutic and delivery approaches using nanotechnology to correct splicing defects underlying disease, Front. Genet., 11, 731, 10.3389/fgene.2020.00731 · DOI
  25. Havens, 2016, Splice-switching antisense oligonucleotides as therapeutic drugs, Nucleic Acids Res., 44, 6549, 10.1093/nar/gkw533 · DOI · Paper page
  26. Rigo, 2014, Antisense oligonucleotide-based therapies for diseases caused by pre-mRNA processing defects, Adv. Exp. Med. Biol., 825, 303, 10.1007/978-1-4939-1221-6_9 · DOI
  27. Bauman, 2009, Therapeutic potential of splice-switching oligonucleotides, Oligonucleotides, 19, 1, 10.1089/oli.2008.0161 · DOI · Paper page
  28. Du, 2009, Progress toward therapy with antisense-mediated splicing modulation, Curr. Opin. Mol. Ther., 11, 116
  29. Peacey, 2012, Targeting a pre-mRNA structure with bipartite antisense molecules modulates tau alternative splicing, Nucleic Acids Res., 40, 9836, 10.1093/nar/gks710 · DOI
  30. Rigo, 2012, Synthetic oligonucleotides recruit ILF2/3 to RNA transcripts to modulate splicing, Nat. Chem. Biol., 8, 555, 10.1038/nchembio.939 · DOI · Paper page
  31. Villemaire, 2003, Reprogramming alternative pre-messenger RNA splicing through the use of protein-binding antisense oligonucleotides, J. Biol. Chem., 278, 50031, 10.1074/jbc.M308897200 · DOI
  32. Bauman, 2011, Modulation of RNA splicing as a potential treatment for cancer, Bioeng. Bugs, 2, 125, 10.4161/bbug.2.3.15165 · DOI
  33. Bauman, 2010, Anti-tumor activity of splice-switching oligonucleotides, Nucleic Acids Res., 38, 8348, 10.1093/nar/gkq731 · DOI
  34. Stepniak-Konieczna, 2020, AON-induced splice-switching and DMPK pre-mRNA degradation as potential therapeutic approaches for myotonic dystrophy type 1, Nucleic Acids Res., 48, 2531, 10.1093/nar/gkaa007 · DOI
  35. Lefave, 2011, Splicing factor hnRNPH drives an oncogenic splicing switch in gliomas, EMBO J., 30, 4084, 10.1038/emboj.2011.259 · DOI
  36. Ward, 2014, Nonsense-mediated decay as a terminating mechanism for antisense oligonucleotides, Nucleic Acids Res., 42, 5871, 10.1093/nar/gku184 · DOI · Paper page
  37. Skordis, 2003, Bifunctional antisense oligonucleotides provide a trans-acting splicing enhancer that stimulates SMN2 gene expression in patient fibroblasts, Proc. Natl. Acad. Sci. U. S. A., 100, 4114, 10.1073/pnas.0633863100 · DOI · Paper page
  38. Becker, 1962, Two families of benign sex-linked recessive muscular dystrophy, Rev. Can. Biol., 21, 551
  39. Becker, 1955, A new x-chromosomal muscular dystrophy, Arch. Psychiatr. Nervenkr. Z. Gesamte Neurol. Psychiatr., 193, 427, 10.1007/BF00343141 · DOI · Paper page
  40. Muntoni, 2003, Dystrophin and mutations: one gene, several proteins, multiple phenotypes, Lancet Neurol., 2, 731, 10.1016/S1474-4422(03)00585-4 · DOI · Paper page
  41. Baccon, 2002, Identification and characterization of Gemin7, a novel component of the survival of motor neuron complex, J. Biol. Chem., 277, 31957, 10.1074/jbc.M203478200 · DOI
  42. Fischer, 1997, The SMN–SIP1 complex has an essential role in spliceosomal snRNP biogenesis, Cell, 90, 1023, 10.1016/S0092-8674(00)80368-2 · DOI · Paper page
  43. Meister, 2001, A multiprotein complex mediates the ATP-dependent assembly of spliceosomal U snRNPs, Nat. Cell Biol., 3, 945, 10.1038/ncb1101-945 · DOI · Paper page
  44. Kamdar, 2016, Dystrophin-deficient cardiomyopathy, J. Am. Coll. Cardiol., 67, 2533, 10.1016/j.jacc.2016.02.081 · DOI · Paper page
  45. Mendell, 2013, Report of MDA muscle disease symposium on newborn screening for Duchenne muscular dystrophy, Muscle Nerve, 48, 21, 10.1002/mus.23810 · DOI · Paper page
  46. Mah, 2014, A systematic review and meta-analysis on the epidemiology of Duchenne and Becker muscular dystrophy, Neuromuscul. Disord., 24, 482, 10.1016/j.nmd.2014.03.008 · DOI · Paper page
  47. Arahata, 1991, Preservation of the C-terminus of dystrophin molecule in the skeletal muscle from Becker muscular dystrophy, J. Neurol. Sci., 101, 148, 10.1016/0022-510X(91)90039-A · DOI
  48. Takeshima, 1995, Modulation of in vitro splicing of the upstream intron by modifying an intra-exon sequence which is deleted from the dystrophin gene in dystrophin Kobe, J. Clin. Invest., 95, 515, 10.1172/JCI117693 · DOI
  49. Dunckley, 1998, Modification of splicing in the dystrophin gene in cultured Mdx muscle cells by antisense oligoribonucleotides, Hum. Mol. Genet., 7, 1083, 10.1093/hmg/7.7.1083 · DOI · Paper page
  50. van Deutekom, 2001, Antisense-induced exon skipping restores dystrophin expression in DMD patient derived muscle cells, Hum. Mol. Genet., 10, 1547, 10.1093/hmg/10.15.1547 · DOI · Paper page
  51. Alter, 2006, Systemic delivery of morpholino oligonucleotide restores dystrophin expression bodywide and improves dystrophic pathology, Nat. Med., 12, 175, 10.1038/nm1345 · DOI · Paper page
  52. Heemskerk, 2010, Preclinical PK and PD studies on 2′-O-methyl-phosphorothioate RNA antisense oligonucleotides in the mdx mouse model, Mol. Ther., 18, 1210, 10.1038/mt.2010.72 · DOI · Paper page
  53. Tanganyika-de Winter, 2012, Long-term exon skipping studies With 2′-O-methyl phosphorothioate antisense oligonucleotides in dystrophic mouse models, Mol. Ther. Nucleic Acids, 1, 10.1038/mtna.2012.38 · DOI
  54. Yokota, 2009, Efficacy of systemic morpholino exon-skipping in Duchenne dystrophy dogs, Ann. Neurol., 65, 667, 10.1002/ana.21627 · DOI · Paper page
  55. Lim, 2017, Eteplirsen in the treatment of Duchenne muscular dystrophy, Drug Des. Devel. Ther., 11, 533, 10.2147/DDDT.S97635 · DOI · Paper page
  56. Wurster, 2018, Antisense oligonucleotides in neurological disorders, Ther. Adv. Neurol. Disord., 11, 10.1177/1756286418776932 · DOI
  57. Kole, 2015, Exon skipping therapy for Duchenne muscular dystrophy, Adv. Drug Deliv. Rev., 87, 104, 10.1016/j.addr.2015.05.008 · DOI · Paper page
  58. Komaki, 2018, Systemic administration of the antisense oligonucleotide NS-065/NCNP-01 for skipping of exon 53 in patients with Duchenne muscular dystrophy, Sci. Transl. Med., 10, 10.1126/scitranslmed.aan0713 · DOI
  59. Heo, 2020, Golodirsen: first approval, Drugs, 80, 329, 10.1007/s40265-020-01267-2 · DOI · Paper page
  60. Kolb, 2011, Spinal muscular atrophy: a timely review, Arch. Neurol., 68, 979, 10.1001/archneurol.2011.74 · DOI · Paper page
  61. Lefebvre, 1995, Identification and characterization of a spinal muscular atrophy-determining gene, Cell, 80, 155, 10.1016/0092-8674(95)90460-3 · DOI · Paper page
  62. Yong, 2004, Why do cells need an assembly machine for RNA–protein complexes?, Trends Cell Biol., 14, 226, 10.1016/j.tcb.2004.03.010 · DOI · Paper page
  63. Mailman, 2002, Molecular analysis of spinal muscular atrophy and modification of the phenotype by SMN2, Genet. Med., 4, 20, 10.1097/00125817-200201000-00004 · DOI · Paper page
  64. Prior, 2004, Homozygous SMN1 deletions in unaffected family members and modification of the phenotype by SMN2, Am. J. Med. Genet. A, 130A, 307, 10.1002/ajmg.a.30251 · DOI · Paper page
  65. Lim, 2001, Modulation of survival motor neuron pre-mRNA splicing by inhibition of alternative 3’ splice site pairing, J. Biol. Chem., 276, 45476, 10.1074/jbc.M107632200 · DOI · Paper page
  66. Miyajima, 2002, Identification of a cis-acting element for the regulation of SMN exon 7 splicing, J. Biol. Chem., 277, 23271, 10.1074/jbc.M200851200 · DOI
  67. Singh, 2006, Splicing of a critical exon of human survival motor neuron is regulated by a unique silencer element located in the last intron, Mol. Cell. Biol., 26, 1333, 10.1128/MCB.26.4.1333-1346.2006 · DOI · Paper page
  68. Baughan, 2009, Delivery of bifunctional RNAs that target an intronic repressor and increase SMN levels in an animal model of spinal muscular atrophy, Hum. Mol. Genet., 18, 1600, 10.1093/hmg/ddp076 · DOI · Paper page
  69. Le, 2005, SMNDelta7, the major product of the centromeric survival motor neuron (SMN2) gene, extends survival in mice with spinal muscular atrophy and associates with full-length SMN, Hum. Mol. Genet., 14, 845, 10.1093/hmg/ddi078 · DOI · Paper page
  70. Hua, 2008, Antisense masking of an hnRNP A1/A2 intronic splicing silencer corrects SMN2 splicing in transgenic mice, Am. J. Hum. Genet., 82, 834, 10.1016/j.ajhg.2008.01.014 · DOI · Paper page
  71. Hua, 2010, Antisense correction of SMN2 splicing in the CNS rescues necrosis in a type III SMA mouse model, Genes Dev., 24, 1634, 10.1101/gad.1941310 · DOI · Paper page
  72. Passini, 2011, Antisense oligonucleotides delivered to the mouse CNS ameliorate symptoms of severe spinal muscular atrophy, Sci. Transl. Med., 3, 10.1126/scitranslmed.3001777 · DOI · Paper page
  73. Singh, 2017, How the discovery of ISS-N1 led to the first medical therapy for spinal muscular atrophy, Gene Ther., 24, 520, 10.1038/gt.2017.34 · DOI · Paper page
  74. Feng, 2016, Pharmacologically induced mouse model of adult spinal muscular atrophy to evaluate effectiveness of therapeutics after disease onset, Hum. Mol. Genet., 25, 964, 10.1093/hmg/ddv629 · DOI
  75. Ratni, 2018, Discovery of risdiplam, a selective survival of motor neuron-2 (SMN2) gene splicing modifier for the treatment of spinal muscular atrophy (SMA), J. Med. Chem., 61, 6501, 10.1021/acs.jmedchem.8b00741 · DOI · Paper page
  76. Sivaramakrishnan, 2017, Binding to SMN2 pre-mRNA–protein complex elicits specificity for small molecule splicing modifiers, Nat. Commun., 8, 1476, 10.1038/s41467-017-01559-4 · DOI · Paper page
  77. Sturm, 2019, A phase 1 healthy male volunteer single escalating dose study of the pharmacokinetics and pharmacodynamics of risdiplam (RG7916, RO7034067), a SMN2 splicing modifier, Br. J. Clin. Pharmacol., 85, 181, 10.1111/bcp.13786 · DOI
  78. Ando, 2020, Discovery of a CNS penetrant small molecule SMN2 splicing modulator with improved tolerability for spinal muscular atrophy, Sci. Rep., 10, 17472, 10.1038/s41598-020-74346-9 · DOI
  79. Goodall, 2021, RNA in cancer, Nat. Rev. Cancer, 21, 22, 10.1038/s41568-020-00306-0 · DOI · Paper page
  80. Graubert, 2011, Recurrent mutations in the U2AF1 splicing factor in myelodysplastic syndromes, Nat. Genet., 44, 53, 10.1038/ng.1031 · DOI · Paper page
  81. Quesada, 2011, Exome sequencing identifies recurrent mutations of the splicing factor SF3B1 gene in chronic lymphocytic leukemia, Nat. Genet., 44, 47, 10.1038/ng.1032 · DOI · Paper page
  82. Rahman, 2020, SnapShot: splicing alterations in cancer, Cell, 180, 208, 10.1016/j.cell.2019.12.011 · DOI
  83. Wang, 2011, SF3B1 and other novel cancer genes in chronic lymphocytic leukemia, N. Engl. J. Med., 365, 2497, 10.1056/NEJMoa1109016 · DOI · Paper page
  84. Cazzola, 2020, Myelodysplastic syndromes, N. Engl. J. Med., 383, 1358, 10.1056/NEJMra1904794 · DOI · Paper page
  85. Harbour, 2013, Recurrent mutations at codon 625 of the splicing factor SF3B1 in uveal melanoma, Nat. Genet., 45, 133, 10.1038/ng.2523 · DOI · Paper page
  86. Martin, 2013, Exome sequencing identifies recurrent somatic mutations in EIF1AX and SF3B1 in uveal melanoma with disomy 3, Nat. Genet., 45, 933, 10.1038/ng.2674 · DOI · Paper page
  87. Suzuki, 2019, Recurrent noncoding U1 snRNA mutations drive cryptic splicing in SHH medulloblastoma, Nature, 574, 707, 10.1038/s41586-019-1650-0 · DOI · Paper page
  88. Shuai, 2019, The U1 spliceosomal RNA is recurrently mutated in multiple cancers, Nature, 574, 712, 10.1038/s41586-019-1651-z · DOI · Paper page
  89. Chen, 2018, The augmented R-loop is a unifying mechanism for myelodysplastic syndromes induced by high-risk splicing factor mutations, Mol. Cell, 69, 412, 10.1016/j.molcel.2017.12.029 · DOI · Paper page
  90. Inoue, 2019, Spliceosomal disruption of the non-canonical BAF complex in cancer, Nature, 574, 432, 10.1038/s41586-019-1646-9 · DOI · Paper page
  91. Agrawal, 2018, Targeting splicing abnormalities in cancer, Curr. Opin. Genet. Dev., 48, 67, 10.1016/j.gde.2017.10.010 · DOI
  92. Eskens, 2013, Phase I pharmacokinetic and pharmacodynamic study of the first-in-class spliceosome inhibitor E7107 in patients with advanced solid tumors, Clin. Cancer Res., 19, 6296, 10.1158/1078-0432.CCR-13-0485 · DOI · Paper page
  93. Hong, 2014, A phase I, open-label, single-arm, dose-escalation study of E7107, a precursor messenger ribonucleic acid (pre-mRNA) splicesome inhibitor administered intravenously on days 1 and 8 every 21 days to patients with solid tumors, Investig. New Drugs, 32, 436, 10.1007/s10637-013-0046-5 · DOI · Paper page
  94. Crews, 2016, RNA splicing modulation selectively impairs leukemia stem cell maintenance in secondary human AML, Cell Stem Cell, 19, 599, 10.1016/j.stem.2016.08.003 · DOI · Paper page
  95. Seiler, 2018, H3B-8800, an orally available small-molecule splicing modulator, induces lethality in spliceosome-mutant cancers, Nat. Med., 24, 497, 10.1038/nm.4493 · DOI · Paper page
  96. Fong, 2019, Therapeutic targeting of RNA splicing catalysis through inhibition of protein arginine methylation, Cancer Cell, 36, 194, 10.1016/j.ccell.2019.07.003 · DOI · Paper page
  97. Radzisheuskaya, 2019, PRMT5 methylome profiling uncovers a direct link to splicing regulation in acute myeloid leukemia, Nat. Struct. Mol. Biol., 26, 999, 10.1038/s41594-019-0313-z · DOI · Paper page
  98. Will, 2001, Spliceosomal UsnRNP biogenesis, structure and function, Curr. Opin. Cell Biol., 13, 290, 10.1016/S0955-0674(00)00211-8 · DOI · Paper page
  99. Turunen, 2013, The significant other: splicing by the minor spliceosome, Wiley Interdiscip. Rev. RNA, 4, 61, 10.1002/wrna.1141 · DOI · Paper page
  100. Daubner, 2012, A syn-anti conformational difference allows SRSF2 to recognize guanines and cytosines equally well, EMBO J., 31, 162, 10.1038/emboj.2011.367 · DOI
  101. Shamoo, 1997, Crystal structure of the two RNA binding domains of human hnRNP A1 at 1.75 Å resolution, Nat. Struct. Biol., 4, 215, 10.1038/nsb0397-215 · DOI
  102. Dietrich, 1997, Terminal intron dinucleotide sequences do not distinguish between U2- and U12-dependent introns, Mol. Cell, 1, 151, 10.1016/S1097-2765(00)80016-7 · DOI
  103. Argente, 2014, Defective minor spliceosome mRNA processing results in isolated familial growth hormone deficiency, Embo Mol. Med., 6, 299, 10.1002/emmm.201303573 · DOI · Paper page
  104. Edery, 2011, Association of TALS developmental disorder with defect in minor splicing component U4atac snRNA, Science, 332, 240, 10.1126/science.1202205 · DOI · Paper page
  105. He, 2011, Mutations in U4atac snRNA, a component of the minor spliceosome, in the developmental disorder MOPD I, Science, 332, 238, 10.1126/science.1200587 · DOI · Paper page
  106. Merico, 2015, Compound heterozygous mutations in the noncoding RNU4ATAC cause Roifman syndrome by disrupting minor intron splicing, Nat. Commun., 6, 8718, 10.1038/ncomms9718 · DOI · Paper page
  107. Cologne, 2019, New insights into minor splicing – a transcriptomic analysis of cells derived from TALS patients, RNA, 25, 1130, 10.1261/rna.071423.119 · DOI
  108. Farach, 2018, The expanding phenotype of RNU4ATAC pathogenic variants to Lowry Wood syndrome, Am. J. Med. Genet. A, 176, 465, 10.1002/ajmg.a.38581 · DOI
  109. Hastings, 2005, An LKB1 AT–AC intron mutation causes Peutz–Jeghers syndrome via splicing at noncanonical cryptic splice sites, Nat. Struct. Mol. Biol., 12, 54, 10.1038/nsmb873 · DOI
  110. Shaw, 2003, Identification of three novel SEDL mutations, including mutation in the rare, non-canonical splice site of exon 4, Clin. Genet., 64, 235, 10.1034/j.1399-0004.2003.00132.x · DOI
  111. Ishihara, 2013, Decreased number of gemini of coiled bodies and U12 snRNA level in amyotrophic lateral sclerosis, Hum. Mol. Genet., 22, 4136, 10.1093/hmg/ddt262 · DOI
  112. Reber, 2016, Minor intron splicing is regulated by FUS and affected by ALS-associated FUS mutants, EMBO J., 35, 1504, 10.15252/embj.201593791 · DOI
  113. Sun, 2015, ALS-causative mutations in FUS/TLS confer gain and loss of function by altered association with SMN and U1-snRNP, Nat. Commun., 6, 6171, 10.1038/ncomms7171 · DOI · Paper page
  114. Li, 2014, SMN control of RNP assembly: from post-transcriptional gene regulation to motor neuron disease, Semin. Cell Dev. Biol., 32, 22, 10.1016/j.semcdb.2014.04.026 · DOI · Paper page
  115. Zhang, 2008, SMN deficiency causes tissue-specific perturbations in the repertoire of snRNAs and widespread defects in splicing, Cell, 133, 585, 10.1016/j.cell.2008.03.031 · DOI · Paper page
  116. Disset, 2006, An exon skipping-associated nonsense mutation in the dystrophin gene uncovers a complex interplay between multiple antagonistic splicing elements, Hum. Mol. Genet., 15, 999, 10.1093/hmg/ddl015 · DOI
  117. Taniguchi-Ikeda, 2011, Pathogenic exon-trapping by SVA retrotransposon and rescue in Fukuyama muscular dystrophy, Nature, 478, 127, 10.1038/nature10456 · DOI · Paper page
  118. Samaranch, 2010, PINK1-linked parkinsonism is associated with Lewy body pathology, Brain, 133, 1128, 10.1093/brain/awq051 · DOI · Paper page
  119. Iovino, 2014, The novel MAPT mutation K298E: mechanisms of mutant tau toxicity, brain pathology and tau expression in induced fibroblast-derived neurons, Acta Neuropathol., 127, 283, 10.1007/s00401-013-1219-1 · DOI · Paper page
  120. Norcliffe-Kaufmann, 2012, Familial dysautonomia (Riley–Day syndrome): when baroreceptor feedback fails, Auton. Neurosci., 172, 26, 10.1016/j.autneu.2012.10.012 · DOI
  121. Otomo, 2005, Electrophysiological and histopathological characteristics of progressive atrioventricular block accompanied by familial dilated cardiomyopathy caused by a novel mutation of lamin A/C gene, J. Cardiovasc. Electrophysiol., 16, 137, 10.1046/j.1540-8167.2004.40096.x · DOI · Paper page
  122. Eriksson, 2003, Recurrent de novo point mutations in lamin A cause Hutchinson–Gilford progeria syndrome, Nature, 423, 293, 10.1038/nature01629 · DOI · Paper page
  123. Muchir, 2000, Identification of mutations in the gene encoding lamins A/C in autosomal dominant limb girdle muscular dystrophy with atrioventricular conduction disturbances (LGMD1B), Hum. Mol. Genet., 9, 1453, 10.1093/hmg/9.9.1453 · DOI · Paper page
  124. Morel, 2006, A LMNA splicing mutation in two sisters with severe Dunnigan-type familial partial lipodystrophy type 2, J. Clin. Endocrinol. Metab., 91, 2689, 10.1210/jc.2005-2746 · DOI · Paper page
  125. Zhu, 2007, A common polymorphism decreases low-density lipoprotein receptor exon 12 splicing efficiency and associates with increased cholesterol, Hum. Mol. Genet., 16, 1765, 10.1093/hmg/ddm124 · DOI · Paper page
  126. Ho, 2015, LDLR gene synonymous mutation c.1813C>T results in mRNA splicing variation in a kindred with familial hypercholesterolaemia, Ann. Clin. Biochem., 52, 680, 10.1177/0004563215572702 · DOI
  127. Tanackovic, 2011, PRPF mutations are associated with generalized defects in spliceosome formation and pre-mRNA splicing in patients with retinitis pigmentosa, Hum. Mol. Genet., 20, 2116, 10.1093/hmg/ddr094 · DOI · Paper page
  128. Vieira, 2014, A defect in the RNA-processing protein HNRPDL causes limb-girdle muscular dystrophy 1G (LGMD1G), Hum. Mol. Genet., 23, 4103, 10.1093/hmg/ddu127 · DOI · Paper page
  129. Bartoletti-Stella, 2017, Messenger RNA processing is altered in autosomal dominant leukodystrophy, Hum. Mol. Genet., 26, 3868, 10.1093/hmg/ddx225 · DOI
  130. Nielsen, 2007, Seemingly neutral polymorphic variants may confer immunity to splicing-inactivating mutations: a synonymous SNP in exon 5 of MCAD protects from deleterious mutations in a flanking exonic splicing enhancer, Am. J. Hum. Genet., 80, 416, 10.1086/511992 · DOI
  131. Thornton, 2014, Myotonic dystrophy, Neurol. Clin., 32, 705, 10.1016/j.ncl.2014.04.011 · DOI · Paper page
  132. Aznarez, 2003, Characterization of disease-associated mutations affecting an exonic splicing enhancer and two cryptic splice sites in exon 13 of the cystic fibrosis transmembrane conductance regulator gene, Hum. Mol. Genet., 12, 2031, 10.1093/hmg/ddg215 · DOI
  133. Kiritsi, 2011, Molecular mechanisms of phenotypic variability in junctional epidermolysis bullosa, J. Med. Genet., 48, 450, 10.1136/jmg.2010.086751 · DOI
  134. Camacho Vanegas, 2001, Ullrich scleroatonic muscular dystrophy is caused by recessive mutations in collagen type VI, Proc. Natl. Acad. Sci. U. S. A., 98, 7516, 10.1073/pnas.121027598 · DOI · Paper page
  135. Barbaux, 1997, Donor splice-site mutations in WT1 are responsible for Frasier syndrome, Nat. Genet., 17, 467, 10.1038/ng1297-467 · DOI · Paper page
  136. Busslinger, 1981, Beta+ thalassemia: aberrant splicing results from a single point mutation in an intron, Cell, 27, 289, 10.1016/0092-8674(81)90412-8 · DOI · Paper page
  137. Treisman, 1983, Specific transcription and RNA splicing defects in five cloned beta-thalassaemia genes, Nature, 302, 591, 10.1038/302591a0 · DOI · Paper page
  138. Tumer, 2013, An overview and update of ATP7A mutations leading to Menkes disease and occipital horn syndrome, Hum. Mutat., 34, 417, 10.1002/humu.22266 · DOI
  139. Yanaizu, 2018, Small nuclear RNA-mediated modulation of splicing reveals a therapeutic strategy for a TREM2 mutation and its post-transcriptional regulation, Sci. Rep., 8, 6937, 10.1038/s41598-018-25204-2 · DOI
  140. van der Woerd, 2015, Analysis of aberrant pre-messenger RNA splicing resulting from mutations in ATP8B1 and efficient in vitro rescue by adapted U1 small nuclear RNA, Hepatology, 61, 1382, 10.1002/hep.27620 · DOI
  141. Coutinho, 2008, Molecular characterization of Portuguese patients with mucopolysaccharidosis IIIC: two novel mutations in the HGSNAT gene, Clin. Genet., 74, 194, 10.1111/j.1399-0004.2008.01040.x · doi:10.1111/j.1399-0004.2008.01040.x
  142. Sathasivam, 2013, Aberrant splicing of HTT generates the pathogenic exon 1 protein in Huntington disease, Proc. Natl. Acad. Sci. U. S. A., 110, 2366, 10.1073/pnas.1221891110 · DOI · Paper page
  143. Chen, 1991, Splice junction mutations in factor IX gene resulting in severe hemophilia B, Nucleic Acids Res., 19, 1172, 10.1093/nar/19.5.1172 · doi:10.1093/nar/19.5.1172
  144. El-Maarri, 2005, Analysis of mRNA in hemophilia A patients with undetectable mutations reveals normal splicing in the factor VIII gene, J. Thromb. Haemost., 3, 332, 10.1111/j.1538-7836.2005.01140.x · DOI
  145. den Hollander, 2006, Mutations in the CEP290 (NPHP6) gene are a frequent cause of Leber congenital amaurosis, Am. J. Hum. Genet., 79, 556, 10.1086/507318 · DOI · Paper page
  146. Olsson, 2008, Myopathy with lactic acidosis is linked to chromosome 12q23.3-24.11 and caused by an intron mutation in the ISCU gene resulting in a splicing defect, Hum. Mol. Genet., 17, 1666, 10.1093/hmg/ddn057 · DOI · Paper page
  147. Mentrup, 2017, A homozygous intronic branch-point deletion in the ALPL gene causes infantile hypophosphatasia, Bone, 94, 75, 10.1016/j.bone.2016.10.022 · DOI
  148. Paron, 2020, Pre-mRNA splicing defects and RNA binding protein involvement in Niemann Pick type C disease, J. Biotechnol., 318, 20, 10.1016/j.jbiotec.2020.03.012 · DOI
  149. Bergsma, 2015, Identification and characterization of aberrant GAA pre-mRNA splicing in pompe disease using a generic approach, Hum. Mutat., 36, 57, 10.1002/humu.22705 · DOI
  150. Kishore, 2006, Regulation of alternative splicing by snoRNAs, Cold Spring Harb. Symp. Quant. Biol., 71, 329, 10.1101/sqb.2006.71.024 · DOI · Paper page
  151. Abuhatzira, 2005, Splicing mutation associated with Rett syndrome and an experimental approach for genetic diagnosis, Hum. Genet., 118, 91, 10.1007/s00439-005-0025-9 · doi:10.1007/s00439-005-0025-9
  152. Osenberg, 2018, Activity-dependent aberrations in gene expression and alternative splicing in a mouse model of Rett syndrome, Proc. Natl. Acad. Sci. U. S. A., 115, E5363, 10.1073/pnas.1722546115 · DOI
  153. Ahmed, 2008, Gene structure and mutant alleles of PCDH15: nonsyndromic deafness DFNB23 and type 1 Usher syndrome, Hum. Genet., 124, 215, 10.1007/s00439-008-0543-3 · DOI
  154. Bestas, 2015, Splice-correction strategies for treatment of X-linked agammaglobulinemia, Curr Allergy Asthma Rep, 15, 510, 10.1007/s11882-014-0510-0 · DOI
  155. Martin, 2012, The survival motor neuron protein forms soluble glycine zipper oligomers, Structure, 20, 1929, 10.1016/j.str.2012.08.024 · DOI
  156. Jagtap, 2020, Identification of phenothiazine derivatives as UHM-binding inhibitors of early spliceosome assembly, Nat. Commun., 11, 5621, 10.1038/s41467-020-19514-1 · DOI

Cited by

See all 71

Metadata

Authors
El Marabti, E., & Abdel-Wahab, O.
Venue
Trends in Molecular Medicine
Publisher
Elsevier BV
Published
2021-07
Volume
27
Issue
7
Pages
643-659
ISSN
1471-4914
Cited by
71
References
13
Language
en
Licence
Funders
  • National Institutes of Health
  • NHLBI (R01 HL128239)
  • NCI (R01 CA242020, R01 CA251138)
  • Edward P. Evans Foundation
  • Henry and Marilyn Taub Foundation

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.